Latest:
Dr Phillips on the Evolution of BTK Inhibitors in MCL
Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Taub, MD, FACS
David Taub, MD, FACS, is an urologist and director of urologic oncology and director of urologic robotic surgery at the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital.
Latest:
Dr Taub on the Benefits of a Multimodal Treatment Approach in Prostate Cancer
David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.
Eric Kumar Singhi, MD
Latest:
Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC
Panelists discuss how financial toxicity and cost-effectiveness analyses highlight the importance of appropriate patient selection for perioperative immunotherapy, while emphasizing that multidisciplinary care and patient involvement remain essential for optimal outcomes.
Haifa Kathrin Al-Ali, MD
Latest:
Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis
Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.
Ruchi J. Desai, MD
Ruchi J. Desai, MD, is an assistant professor in the Division of Hematology, Oncology, and Palliative Care at the Virginia Commonwealth University (VCU) School of Medicine as well as a hematologist/oncologist in the Department of Internal Medicine at VCU Health.
Latest:
Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies
Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.
Saad Usmani, MD, MBA, FACP, FASCO
Latest:
Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
Ann M. Gillenwater, MD
Latest:
Dr Gillenwater on Phase 1 Data for ASP-1929 Plus Pembrolizumab in HNSCC
Ann M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.